2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.24: Analysis of Survival and Factors Associated with Clinical Benefit and Death in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR gene mutations, experience at an institution

PP01.24: Analysis of Survival and Factors Associated with Clinical Benefit and Death in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR gene mutations, experience at an institution

Back to course

Pdf Summary

The study focuses on advanced non-small cell lung cancer (NSCLC) in patients with EGFR gene mutations at a Colombian institution, analyzing survival and factors affecting clinical outcomes. NSCLC with EGFR mutations varies by genetic and ethnic factors, impacting prognosis. The retrospective cohort study involved 16 patients with stage IV NSCLC and utilized logistic regression and support vector machines (SVM) to evaluate survival and mortality-associated factors.<br /><br />Key findings include:<br />- Female patients had a lower mortality rate.<br />- Patients aged 41-75 demonstrated lower mortality, possibly due to better access to treatment.<br />- Chronic obstructive pulmonary disease (COPD) was linked to improved treatment response, attributed to focused medical attention specific to the disease.<br />- Patients from higher socioeconomic backgrounds had lower mortality, but this observation needs deeper exploration to consider disparities in healthcare access and disease characteristics.<br />- Co-existing EGFR and KRAS mutations were correlated with higher mortality.<br />- Current smoking and a family history of lung cancer were slightly associated with an increased risk of death.<br />- The median overall survival for patients with the L858R mutation was 43 months, while those treated with Osimertinib had a median survival of 41.6 months.<br /><br />The study highlights the complexity of NSCLC prognosis amidst genetic variations, suggesting that specific mutations like L858R and treatments like Osimertinib may confer better outcomes. However, due to a small sample size, the study calls for further research with larger populations to confirm these findings, as well as to explore the socioeconomic and treatment access factors affecting survival rates.

Asset Subtitle

Andres Felipe Bejarano

Keywords

NSCLC

EGFR mutations

survival analysis

Colombian institution

logistic regression

support vector machines

socioeconomic factors

L858R mutation

Osimertinib

prognosis